3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Squamous Cell Carcinoma of Head and Neck
5
Skin Neoplasms
5
Neoplasm Metastasis
5
Melanoma
5
Lung Neoplasms
5
Carcinoma
5
Recurrence
4
Neoplasms
4
Mouth Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Adenocarcinoma
3
Ovarian Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, B-Cell
2
Laryngeal Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Squamous Cell
2
Vaccinia
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Solid Tumors
1
Interventions
Radiosurgery
23
Temozolomide
14
Magnetic Resonance Spectroscopy
14
pembrolizumab
11
Bevacizumab
11
Nivolumab
10
Ipilimumab
8
Specimen Handling
6
Memantine
6
abemaciclib
5
Radiotherapy
5
Mental Status and Dementia Tests
5
Blood Specimen Collection
5
Radiation
4
entrectinib
3
Surveys and Questionnaires
3
Sodium Chloride
3
Saline Solution
3
Receptors, Interleukin-8B
3
Proton Therapy
3
Lomustine
3
trastuzumab deruxtecan
2
trametinib
2
pertuzumab
2
osimertinib
2
lenvatinib
2
fluciclovine F-18
2
contrast agent BR1
2
atezolizumab
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
cemiplimab
×
90 days
×
Clear all
NCT05317858
2026-04-16
LIMITLESS
InSightec
Phase 3
Recruiting
30 enrolled